

Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (Optimus) Study D. J. Angiolillo, et al. Circulation (2007) 115;708-16 


Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin A. A. Bartolucci and G. Howard Am J Cardiol (2006) 98;746-50 


Effectiveness of Same Day Percutaneous Coronary Intervention Followed by Minimally Invasive Aortic Valve Replacement for Aortic Stenosis and Moderate Coronary Disease ("Hybrid Approach") D. R. Brinster, et al. Am J Cardiol (2006) 98;1501-1503

Effectiveness and Safety of Glycoprotein Iib/Iiia Inhibitors and Clopidogrel Alone and in Combination in Non-St-Segment Elevation Myocardial Infarction (from the National Registry of Myocardial Infarction-4) G. Bromberg-Marin, et al. Am J Cardiol (2006) 98;1125-31


Evolving Management of St-Segment Elevation Myocardial Infarction: Update on Recent Data C. P. Cannon Am J Cardiol (2006) 98;10Q-21Q

Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy C. P. Cannon and D. S. McLean Am J Cardiol (2006) 98;S33-S38
Ischemic and Bleeding Outcomes in Women Treated with Bivalirudin During Percutaneous Coronary Intervention: A Subgroup Analysis of the Randomized Evaluation in Pci Linking Angiomax to Reduced Clinical Events (Replace)-2 Trial M. Chacko, et al. Am Heart J (2006) 151;1032 e1-7


Association between Level of Platelet Inhibition after Early Use of Abciximab and Myocardial Reperfusion in St-Elevation Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention A. P. de Prado, et al. Am J Cardiol (2006) 97;798-803


Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated with Higher Platelet Counts in Patients with St-Elevation Myocardial Infarction (Results from Clarity-Timi 28) C. M. Gibson, et al. Am J Cardiol (2006) 98;761-3


Initial Experience with an Intravenous P2y12 Platelet Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention: Results from a 2-Part, Phase II, Multicenter, Randomized, Placebo- and Active-Controlled Trial A. B. Greenbaum, et al. Am Heart J (2006) 151;689 e1-689 e10


Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients with Coronary Artery Stents: A Science Advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and


Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary
Long-Term Cost-Effectiveness of Early and Sustained Clopidogrel Therapy for up to 1 Year in Patients Undergoing Percutaneous Coronary Intervention after Presenting with Acute Coronary Syndromes without St-Segment Elevation E. M. Mahoney, et al. Am Heart J (2006) 151;219-27
Comparison of Aspirin Resistance in Type 1 Versus Type 2 Diabetes Mellitus S. S. Mehta, et al. Am J Cardiol (2006) 97;567-70


A Double-Blind, Randomized Study on Platelet Aggregation in Patients Treated with a Daily Dose of 150 or 75 Mg of Clopidogrel for 30 Days N. von Beckerath, et al. Eur Heart J (2007)

A Novel Enoxaparin Regime for St Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A West Sub-Study R. C. Welsh, et al.


Detection of Von Willebrand Factor and Tissue Factor in Platelets-Fibrin Rich Coronary


Reduced 6-Month Resource Use and Costs Associated with Cilostazol in Patients after Successful Coronary Stent Implantation: Results from the Cilostazol for Restenosis (Crest) Trial. Z. Zhang, et al. Am Heart J (2006) 152;770-6